Indices extend losses; pharma stocks rally

Image
Capital Market
Last Updated : Apr 06 2022 | 10:50 AM IST
Benchmark indices extended losses in morning trade. The Nifty held on to 17,800 mark. Media, pharmaceutical and oil & gas stocks were in demand while banking and financial shares corrected for second day.

At 10:22 IST, the S&P BSE Sensex declined 473.82 points or 0.79% to 59,702.2. The Nifty 50 index shed 122.85 points or 0.68% at 17,834.1.

The broader market traded with gains. The S&P BSE Mid-Cap index rose 0.29% while the S&P BSE Small-Cap index gained 0.41%.

The market breadth, indicating the overall health of the market, was strong. On the BSE, shares 1892 rose and 1224 shares fell. A total of 118 shares were unchanged.

RBI MPC meet:

The Reserve Bank of India (RBI)'s Monetary Policy Committee (MPC) will be holding its first meeting of the fiscal year 2022-23 fiscal from 6 April to 8 April. MPC's interest rate decision will be announced on 8 April 2022. In the previous meeting, MPC kept the policy repo rate under the liquidity adjustment facility (LAF) unchanged at 4%.

Buzzing Index:

The Nifty Pharma index gained 0.59% to 13,890.05, extending its winning run to third trading session. The pharmaceutical index has added 2.28% in three days.

Strides Pharma Science (up 3.57%), Glenmark Pharma (up 1.49%), Biocon (up 1.21%), Aurobindo Pharma (up 1.13%), Zydus Lifesciences (up 0.99%) and Alkem Laboratories (up 0.96%) were top gainers in pharmaceutical space.

Stocks in Spotlight:

Tata Steel advanced 1.57% to Rs 1366 after the company's India business achieved its highest-ever annual crude steel production of 19.06 million tons in FY22, registering a growth of 13% YoY. During Q4 FY22, Tata Steel India's crude steel production stood at 4.90 million tons, up 2% QoQ. In Q4 FY22, deliveries grew by 16% QoQ to 5.12 million tons.

Marico fell 3.48% to Rs 524.95 after the company said that FMCG volumes declined in the January-February 2022 period on a year-on-year basis. The FMCG major said that in Q4 quarter, consumption trends remained subdued amid weak rural sentiment and inflation in global commodities due to geopolitical tensions. Consolidated revenue growth in the quarter touched high single digits, it said. The company expects a "marginal growth" in profits in Q4 due to a rise in input costs and higher advertising and promotional spending. "While companies affected price hikes across FMCG categories to cope with the cost-push, persistent inflation continued to hurt consumer wallets across rural and urban," it added.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 06 2022 | 10:24 AM IST

Next Story